Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.

导出原文传递

翻译打印收藏纠错

作者： Riccardo,Lobefaro ^[1] ; Luigi,Mariani ^[2] ; Giorgia,Peverelli ^[1] ; Francesca,Ligorio ^[1] ; Giovanni,Fucà ^[1] ; Alessandro,Rametta ^[1] ; Emma,Zattarin ^[1] ; Rita,Leporati ^[1] ; Daniele,Presti ^[1] ; Beatrice,Cantarelli ^[3] ; Catherine,Depretto ^[4] ; Andrea,Vingiani ^[5] ; Siranoush,Manoukian ^[6] ; Gianfranco,Scaperrotta ^[4] ; Giulia V,Bianchi ^[1] ; Giuseppe,Capri ^[1] ; Giancarlo,Pruneri ^[5] ; Filippo,de Braud ^[7] ; Claudio,Vernieri ^[8]

作者单位： Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[1] Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[2] IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy. ^[3] Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[4] Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Haematology, University of Milan, Milan, Italy. ^[5] Unit of Medical Genetics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[6] Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Haematology, University of Milan, Milan, Italy. ^[7] Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy. Electronic address: claudio.vernieri@istitutotumori.mi.it. ^[8]

关键词 Advanced triple-negative breast cancer Carboplatin- gemcitabine Carboplatin-paclitaxel Overall Survival Progression Free Survival